Becky Pferdehirt is a partner on the bio investing team. She focuses on early stage companies building technology platforms for therapeutic discovery and development.
Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen R&D, focused on cell and gene therapy technology innovation.
Becky completed her postdoctoral education at Genentech studying cancer cell biology and proteomics. She holds a PhD in Molecular and Cellular Biology from UC Berkeley and a BS in Biology from MIT.
_______________________
Join BIOS Community 🎉
Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, & invite-only events…
Apply to Join —https://docs.google.com/forms/d/e/1FA...
For More Interesting Content 💭
🦾 Website: https://www.bios.community/
🧬 Podcast: https://open.spotify.com/show/2HmcPq9...
🧪 Medium: / bios
🩺 Twitter: / bios_community
🦠 LinkedIn: / bios-community
🧠 Substack: https://bioscommunity.substack.com
_______________________
BIOS: Nucleus of Life Science Innovation 🚀
Alix Ventures: Driving Patient Impact - Supporting Early Stage Startups Engineering Biology to Create Radical Advances in Human Health🌟
_____________________
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement or recommendation by Alix Ventures, BIOS Community, or its affiliates. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Alix Ventures employees are those of the employees and do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, and content sponsors.